A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s Ranibizumab with Lucentis(®) in patients with neovascular age-related macular degeneration

PURPOSE: The present study compares the efficacy, safety, and immunogenicity of Lupin’s biosimilar ranibizumab with that of Lucentis(®) in patients with neovascular age-related macular degeneration. METHODS: This prospective, double-blind, multi-centric phase-III study was conducted across 19 center...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Ramandeep, Chauhan, Rohan, Saxena, Ashish, Shah, Anup, Mondal, Laxshmi, Bakhle, Dhananjay, Shah, Chirag, Shah, Arpit, Deoghare, Shashank, Krishnan, Neelakant, Godse, Neelima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Special Focus, Retina, Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672715/
https://www.ncbi.nlm.nih.gov/pubmed/35918962
http://dx.doi.org/10.4103/ijo.IJO_2118_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672715/
https://www.ncbi.nlm.nih.gov/pubmed/35918962
http://dx.doi.org/10.4103/ijo.IJO_2118_21

Ejemplares similares